We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Unapproved Drug Product Names Stay Out of Module 3 Metadata
Unapproved Drug Product Names Stay Out of Module 3 Metadata
January 28, 2011
Sponsors should work with the FDA during the investigational new drug stage and prior to resubmission of the new drug application (NDA) to determine a proprietary name for the product.